Medtronic CEO pitches strategy revamp, but Wall Street takes wait-and-see approach

Geoff Martha laid out a new operating model to investors, acknowledging the medtech giant has too often grown "below its markets" and that its market share is "not commensurate with our technology leadership."

By Greg Slabodkin • Oct. 14, 2020

With rivals delayed, Intuitive Surgical extends use of robotic instruments

The program could help expand the da Vinci robot's place in gallbladder removal and hernia repair, as Medtronic and J&J face pandemic-related delays to launching their systems. 

By Susan Kelly • Oct. 14, 2020

Explore the Trendline➔

Medical device industry continues to turn to AI

While the industry continues to embrace artificial intelligence, there are still questions about how the new technologies need to be regulated and if they are effective.

By MedTech Dive staff

Old market, new growth: Medtronic and Axonics competition ups sacral neuromodulation's reach

In a challenging year for elective procedures, Medtronic estimates a key pelvic health market that's grown in the mid-single digits for the last 25 years increased 20% this past quarter.

By Maria Rachal • Oct. 14, 2020

Elective surgeries seen driving Q3 medtech comeback, but can it last?

A robust recovery in medical device procedures is forecast for the third quarter as patients rescheduled, but some analysts are now seeing a leveling off in hospital activity. The flu season also poses a risk going into the winter.

By Susan Kelly • Oct. 13, 2020

J&J US device unit returns to growth, potential bellwether for medtech Q3 earnings

A double-digit rise in interventional sales was offset by ongoing headwinds in parts of the orthopaedic and surgery franchises.

By Nick Paul Taylor • Oct. 13, 2020

De Novo-winning devices often lack effectiveness data, analysis shows

A JAMA Internal Medicine analysis of 63 devices reviewed via FDA's premarket pathway for novel technologies found one-fifth weren't evaluated in pivotal studies.

By Nick Paul Taylor • Oct. 13, 2020

TCT 2020: Abbott devices, TAVR systems headline late breaker lineup

The five-day Transcatheter Cardiovascular Therapeutics event kicked off Wednesday.

By Susan Kelly • Oct. 12, 2020

Cancer testing drives 2020 medtech IPO surge after slow start

A flurry of activity began in June, including from China-based Burning Rock and Genetron and U.S.-based Progenity.

By Nick Paul Taylor • Oct. 12, 2020

5 key exec insights from 2020's MedTech Conference

Top leaders from Abbott, BD, Medtronic, Stryker and Zimmer Biomet shared the latest on the industry's recovery during the pandemic and thoughts on where it goes from here.

By Maria Rachal • Oct. 9, 2020

Fresenius sees COVID-19 driving dialysis device growth, eyes home care strategy

Execs at the company, which upped production of machines by 230% in response to the crisis, laid out plans at an investor day Thursday.

By Nick Paul Taylor • Oct. 9, 2020

Medtronic shares early data TAVR works in low-risk bicuspid patients

Authors of the short Medtronic-sponsored trial, published in JAMA Cardiology, suggest the valve may be free of problems that caused early studies of the device in bicuspid disease to report worse in-hospital outcomes.

By Nick Paul Taylor • Oct. 8, 2020

Avail raises $100M to let medtech reps remotely oversee surgeries

The Series B funding comes weeks after Smith & Nephew claimed to be the first orthopaedics company to use the telemedicine service.

By Nick Paul Taylor • Oct. 8, 2020

Steris inks $850M deal for Key Surgical adds to medtech M&A wave

CEO Walter Rosebrough gave a nod to current low interest rates but said Steris had been looking at this potential transaction "for years, not months."

By Susan Kelly • Oct. 7, 2020

'Tragedy' if FDA doesn't extend COVID-19 lessons beyond pandemic, Shuren says

Device head Jeff Shuren acknowledged the regulatory paradigm for medical devices is more than 40 years old and "not well suited for many modern-day technologies," speaking at AdvaMed's Virtual MedTech Conference.

By Greg Slabodkin • Oct. 7, 2020

Analysts predict Zimmer Biomet M&A in 2021 to speed growth

The medtech is likely to initially target private orthopaedic companies worth up to $300 million, Needham analysts specified. The spine and dental businesses, meanwhile, could be on the chopping block.

By Nick Paul Taylor • Oct. 7, 2020

App-connected pacemakers, telehealth among Cleveland Clinic top 2021 innovations

Medtronic's MyCareLink Heart pacemaker smartphone app is one example of the four medtech developments making the annual top 10 list of medical breakthroughs.

By Nick Paul Taylor • Oct. 7, 2020

CMS officials elaborate on proposed breakthrough device coverage pathway

Agency representatives fleshed out details of proposed reimbursement meant to speed coverage of these technologies in a townhall webcast during AdvaMed's Virtual MedTech Conference.

By Susan Kelly • Oct. 6, 2020

Medical Alley, GI docs push to ease CMS device pass-through payments

The trade group for Medtronic, Boston Scientific and other medtech giants wants to bar Medicare contractors from making regional coverage decisions that obstruct transitional pass-through payments.

By Susan Kelly , Maria Rachal • Oct. 6, 2020

M&A on horizon as deep-pocketed medtechs eye distressed assets: EY

The combination of smaller companies questioning their pandemic survival and larger companies with considerable capital may spark a buying surge, the consultancy said in its annual medtech report.

By Nick Paul Taylor • Oct. 6, 2020

AdvaMed sends CMS reform wishlist to boost digital health device coverage

The medtech industry group argues changes are needed for Medicare to realize the potential of a sector projected to be worth $500 billion by 2026.

By Nick Paul Taylor • Oct. 2, 2020

Smith & Nephew, Quidel forecasts may signal improving ortho, diagnostics markets

The preliminary Q3 results are a positive sign for elective surgery volumes at other orthopaedics competitors such as J&J and Stryker and for COVID-19 antigen testing businesses including Abbott and BD.

By Nick Paul Taylor • Oct. 2, 2020

Ethylene oxide sterilizer rule pushed back by EPA

FDA held a related advisory panel late last year, where one member said the shutdown of device sterilization plants put the U.S. "on the cusp of a major medical logistical failure." COVID-19 has shifted the landscape.

By Maria Rachal • Oct. 1, 2020

5 ways COVID-19 is reshaping the medtech industry

Remote tech, clinical trials and marketing are a few of the areas disrupted by the pandemic this year — with changes that look set to stick around.

By Maria Rachal , Greg Slabodkin • Oct. 1, 2020

Medtronic hit with DOJ ventilator antitrust probe

The investigation comes amid allegations that industry consolidation contributed to a shortage of the breathing devices during the early months of the COVID-19 pandemic.   

By Greg Slabodkin • Oct. 1, 2020

AtriCure stock recovers after short seller predicts 'complete collapse' of business

Shares in the atrial fibrillation medtech were down 14% immediately following a scathing report. Analysts at SVB Leerink rebutted the grim assessment from Kerrisdale Capital.

By Nick Paul Taylor • Oct. 1, 2020